Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Stromacel, Inc.
A review of tech transfer deals over 10 years shows that licensees often protect their value positions to limit royalties paid out to licensors. Meanwhile, licensors often protect their future rights with language recognizing that additional parties may be involved in producing a final product.
Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.
Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.
Tapping key external partners including the government, industry and academic partners in China is high on the agenda as Johnson & Johnson opens its first Asia Innovation Center.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Proteoderm Inc.
- Proteonomix, Inc.